AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|
22.6 C
New York
Monday, June 22, 2026

Tag: therapeutics

newssourceFORcompanyinformationcontent1marketreleases

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. He takes over from Ruth McKernan, who retains her role on the Board as a Director and Interim Chief Executive Officer (CEO).

AXA and China Biotech Services Sign Memorandum of Understanding

Joint effort to explore innovative cancer treatment solutions and broaden options for customers HONG KONG, July 15, 2025 /PRNewswire/ -- AXA China Region Insurance Company...

Topflight Pharma Development Veteran Joins Synendos

Dr. George Garibaldi is named Chief Medical Officer as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy.

Divamics’ AI and Molecular Dynamics Platform Powers Breakthroughs in Metabolic Disease Drug Discovery for Partners

SUZHOU, China, July 15, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through...

Divamics’ AI and Molecular Dynamics Platform Powers Breakthroughs in Metabolic Disease Drug Discovery for Partners

SUZHOU, China, July 14, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through...

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the...

-          The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of...

MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight

While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipeline is positioned to expand the class into mainstream disorders....

MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight

While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipeline is positioned to expand the class into mainstream disorders....

Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

PITTSBURGH, July 14, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on human longevity and healthy aging (“Longevity”, the “Company”, “we”, “our”, or “us”), today announced the execution of a definitive merger agreement (the “Merger”) with True Health Inc., a leading player in the fast growing plasma collection industry under the THPlasma brand (“THPlasma”), to combine the companies in an all-stock transaction. Following the closing of the Merger (the “Closing”), the combined company is expected to continue to trade on Nasdaq under the symbol “XAGE.”

Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue

ORLANDO, Fla., July 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy Inc. (OTC: BLEG), a diversified holdings company, today announced significant changes in its leadership structure and a strategic merger initiative aimed at positioning the company for growth in the burgeoning addiction therapeutics sector.

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions...

WARREN, N.J., July 14, 2025 (GLOBE NEWSWIRE) --  Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, in collaboration with Microsoft (Nasdaq: MSFT) and Databricks, has successfully built the alpha version of its foundational PredicTcell™ model.

Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa

First modules of BLA submitted to FDA under rolling review, with full submission anticipated in early 2026MCO-010 BLA for retinitis pigmentosa is eligible for priority review...

Waters and BD’s Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable...

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared...

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapeutics

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers